Table 2.

Characteristics of the 151 women in this study classified as having high risk of developing breast cancer (>8% 10-year risk) using the Tyrer–Cuzick model, compared with those not at high risk of breast cancer (≤8% 10-year risk)

CharacteristicsHigh-risk womenNon-high–risk women
Number1514115
Age group
 40–4919.2%29.9%
 50–5931.1%31.4%
 60–6931.8%28.0%
 70–7917.9%10.6%
 Median age, y (SD)59 (9.8)56 (9.6)
BMI
 <2540.9%50.2%
 ≥2559.1%49.8%
Biopsy findings
 Previous biopsy29.1%16.1%
 Hyperplasia2.6%0.5%
 Atypical hyperplasia4.0%0.0%
 LCIS1.3%0.0%
Personal cancer history
 Ovarian cancer2.6%0.7%
Genetic testing
BRCA1/2-positive2.0%0.0%
 Results pending2.0%0.2%
 Ashkenazi inheritance3.3%1.2%
Reproductive history
 Age at menarche ≤1122.5%17.0%
 Age at menopause ≥5515.9%7.8%
 Nulliparous30.9%19.6%
 First birth age <200.7%7.6%
 First birth age ≥3026.8%20.2%
 Mean age first birth, y (SD)28.4 (5.1)26.1 (5.4)
HRT use
 Current HRT user15.9%9.5%
 Estrogen-only70.8%53.6%
 Combined29.2%46.4%
 Mean length of time on HRT, y (SD)19.8 (12.9)9.2 (8.1)
Family cancer history
 ≥1 first-degree relativea with:
  Breast cancer83.4%12.0%
  Bilateral breast cancer25.2%0.6%
  Ovarian cancer5.3%3.0%
  Both breast and ovarian cancer2.6%0.2%
  Breast/bilateral breast cancer diagnosis age <5028.5%4.3%
 ≥1 relativeb with:
  Breast cancer94.0%32.0%
  Bilateral breast cancer35.1%3.5%
  Ovarian cancer11.3%8.3%
  Both breast and ovarian cancer10.6%3.1%
  Breast/bilateral breast cancer diagnosis age <5038.4%9.3%
Relatives per respondent:
 Diagnosed with cancerc
  Mean number (SD)3.2 (2.1)2.3 (1.8)
  Range1–131–16
 Diagnosed with breast cancer (including bilateral)
  Mean number (SD)2.1 (1.2)1.4 (0.7)
  Range1–81–6
Percent Eligible:
 For MRI screening (BRCA1/2 criteria)2.6%0.1%
 For referral to HCP30.5%6.1%

Abbreviation: HCP, Hereditary Cancer Program.

  • aFirst-degree relatives include parents, siblings, and children.

  • bSecond- and third-degree relatives also include grandparents, aunts, uncles, cousins, and grandchildren.

  • cTypes of cancer included breast, bilateral breast, ovarian, and other (i.e., prostate, skin, gastrointestinal, lung, etc.).